These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 18612893)

  • 1. Asthma 2008: targeting immunoglobulin E to achieve disease control.
    Prenner BM
    J Asthma; 2008 Aug; 45(6):429-36. PubMed ID: 18612893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-immunoglobulin E therapy with omalizumab for asthma.
    Hendeles L; Sorkness CA
    Ann Pharmacother; 2007 Sep; 41(9):1397-410. PubMed ID: 17698897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoglobulin E-mediated airway inflammation is active in most patients with asthma.
    Hayden ML
    J Am Acad Nurse Pract; 2007 Sep; 19(9):439-49. PubMed ID: 17760568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma.
    Bousquet J; Cabrera P; Berkman N; Buhl R; Holgate S; Wenzel S; Fox H; Hedgecock S; Blogg M; Cioppa GD
    Allergy; 2005 Mar; 60(3):302-8. PubMed ID: 15679714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
    Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N
    J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One year treatment with omalizumab is effective and well tolerated in Japanese Patients with moderate-to-severe persistent asthma.
    Ohta K; Yamamoto M; Sato N; Ikeda K; Miyamoto T
    Allergol Int; 2010 Jun; 59(2):167-74. PubMed ID: 20179417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-IgE in severe persistent allergic asthma.
    Fox H
    Respirology; 2007 Nov; 12 Suppl 3():S22-8; discussion S45-7. PubMed ID: 17956516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality.
    Holgate S; Bousquet J; Wenzel S; Fox H; Liu J; Castellsague J
    Curr Med Res Opin; 2001; 17(4):233-40. PubMed ID: 11922396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.
    Sullivan SD; Turk F
    Allergy; 2008 Jun; 63(6):670-84. PubMed ID: 18445184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab.
    Nowak D
    Respir Med; 2006 Nov; 100(11):1907-17. PubMed ID: 16949266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases.
    D'Amato G
    Eur J Pharmacol; 2006 Mar; 533(1-3):302-7. PubMed ID: 16464445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omalizumab in the treatment of severe asthma: efficacy and current problems.
    Pelaia G; Renda T; Romeo P; Busceti MT; Maselli R
    Ther Adv Respir Dis; 2008 Dec; 2(6):409-21. PubMed ID: 19124386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis.
    Busse WW; Massanari M; Kianifard F; Geba GP
    Curr Med Res Opin; 2007 Oct; 23(10):2379-86. PubMed ID: 17711616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-IgE therapy with omalizumab in asthma and allergic rhinitis.
    Dodig S; Richter D; Cepelak I; Benko B
    Acta Pharm; 2005 Jun; 55(2):123-38. PubMed ID: 16179127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating moderate-to-severe allergic asthma with anti-IgE monoclonal antibody (omalizumab). An update.
    D'Amato G; Perticone M; Bucchioni E; Salzillo A; D'Amato M; Liccardi G
    Eur Ann Allergy Clin Immunol; 2010 Aug; 42(4):135-40. PubMed ID: 21114196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
    Holgate ST; Djukanović R; Casale T; Bousquet J
    Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment.
    Peters SP; Ferguson G; Deniz Y; Reisner C
    Respir Med; 2006 Jul; 100(7):1139-51. PubMed ID: 16713224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omalizumab: new drug. Asthma: too many unknowns for an anti-IgE.
    Prescrire Int; 2007 Oct; 16(91):179-82. PubMed ID: 17926440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoglobulin E blockade in the treatment of asthma.
    Kuhn R
    Pharmacotherapy; 2007 Oct; 27(10):1412-24. PubMed ID: 17896896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.